| Literature DB >> 33801925 |
Maria Cristina Barbalace1, Lorenzo Zallocco2, Daniela Beghelli3, Maurizio Ronci4,5, Serena Scortichini6, Maria Digiacomo2, Marco Macchia2, Maria Rosa Mazzoni2, Dennis Fiorini6, Antonio Lucacchini7, Silvana Hrelia1, Laura Giusti8, Cristina Angeloni8.
Abstract
Neurodegenerative diseases are driven by several mechanisms such as inflammation, abnormal protein aggregation, excitotoxicity, mitochondrial dysfunction and oxidative stress. So far, no therapeutic strategies are available for neurodegenerative diseases and in recent years the research is focusing on bioactive molecules present in food. In particular, extra-virgin olive oil (EVOO) phenols have been associated to neuroprotection. In this study, we investigated the potential antioxidant and neuroprotective activity of two different EVOO extracts obtained from Quercetano cultivar trees grown in two different areas (plain and hill) of the Tuscany region (Italy). The different geographical origin of the orchards influenced phenol composition. Plain extract presented a higher content of phenyl ethyl alcohols, cinnammic acids, oleacein, oleocanthal and flavones; meanwhile, hill extract was richer in lignans. Hill extract was more effective in protecting differentiated SH-SY5Y cells from peroxide stress thanks to a marked upregulation of the antioxidant enzymes heme oxygenase 1, NADPH quinone oxidoreductase 1, thioredoxin Reductase 1 and glutathione reductase. Proteomic analysis revealed that hill extract plays a role in the regulation of proteins involved in neuronal plasticity and activation of neurotrophic factors such as BDNF. In conclusion, these data demonstrate that EVOOs can have important neuroprotective activities, but these effects are strictly related to their specific phenol composition.Entities:
Keywords: antioxidants; neuroprotection; neurotrophins; olive oil; oxidative stress; phenols; proteomics
Year: 2021 PMID: 33801925 PMCID: PMC8000409 DOI: 10.3390/antiox10030421
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
List of primers for real-time PCR in SH-SY5Y cells.
| Gene | 5′-Forward-3′ | 5′-Reverse-3′ | RefSeq Accession No. |
|---|---|---|---|
| HMOX1 | CAACAAAGTGCAAGATTCTG | TGCATTCACATGGCATAAAG | NM_002133 |
| BDNF | CAAAAGTGGAGAACATTTGC | AACTCCAGTCAATAGGTCAG | NM_001143811 |
| NQO1 | AGTATCCACAATAGCTGACG | TTTGTGGGTCTGTAGAAATG | NM_000903 |
| GSR | GACCTATTCAACGAGCTTTAC | CAACCACCTTTTCTTCCTTG | NM_000637 |
| TXNRD1 | AGACAGTTAAGCATGATTGG | AATTGCCCATAAGCATTCTC | NM_001093771 |
| 18S rRNA | CAGAAGGATGTAAAGGATGG | TATTTCTTCTTGGACACACC | NM_022551 |
Type of soil in hill and plain orchards a.
| Soil Categories | Hill | Plain |
|---|---|---|
| % ± SEM | % ± SEM | |
| Clay | 8.7 ± 0.08 * | 8.4 ± 0.08 |
| Silt | 38 ± 0.46 *** | 46.1 ± 0.50 |
| Sandy | 53.3 ± 0.68 ** | 45.6 ± 0.94 |
| pH | 5.4 ± 0.04 *** | 6.9 ± 0.05 |
| Ppm ± | Ppm ± | |
| K | 110 ± 0.83 *** | 54.7 ± 0.44 |
| Mg | 73.7 ± 0.47 *** | 63.6 ± 0.37 |
| Ca | 1188 ± 10.29 *** | 1428 ± 15.46 |
| P | 48 ± 0.36 *** | 34 ± 0.22 |
| Total N | 2600 ± 24.02 *** | 3000 ± 27.71 |
a Asterisks after the phenolic substance’s name indicate the level of significance (One way ANOVA, Tukey’s test for pairwise comparison) in the difference between Hill and Plain extracts: * p < 0.05; ** p < 0.01; *** p < 0.001; Analyses were carried out by the “Regional laboratory for soil analysis and plant production” http://www.agriligurianet.it (accessed 21 January 2021).
Concentration of the main polar phenolic components in hill and plain EVOO’s extracts.
| Phenolic Compound | Hill | Plain |
|---|---|---|
| (μg/g ± SD) | ||
| Hydroxytyrosol ** | 678.21 ± 24.27 | 2167.85 ± 93.35 |
| Tyrosol ** | 771.82 ± 38.75 | 1697.46 ± 123.03 |
| Vanillic acid ** | 6.83 ± 0.34 | 4.05 ± 0.15 |
| p-Coumaric acid ** | 3.22 ± 0.19 | 10.30 ± 0.67 |
| ferulic acid * | 0.56 ± 0.04 | 0.89 ± 0.05 |
| 3,4-DHPEA-EDA ** | 803.33 ± 46.12 | 2610.92 ± 169.48 |
| p-HPEA-EDA | 1102.60 ± 71.26 | 1316.25 ± 95.03 |
| Pinoresinol ** | 1819.41 ± 51.98 | 664.64 ± 23.78 |
| Acetoxypinoresinol ** | 1854.62 ± 133.24 | 1018.40 ± 80.94 |
| Luteolin | 64.27 ± 4.15 | 85.78 ± 6.19 |
| 3,4-DHPEA-EA * | 330.78 ± 9.45 | 244.55 ± 8.75 |
| p-HPEA-EA ** | 756.07 ± 54.32 | 251.74 ± 20.01 |
| Apigenin * | 25.08 ± 1.08 | 40.08 ± 2.02 |
Asterisks after the phenolic substance’s name indicate the level of significance (One way ANOVA, Tukey’s test for pairwise comparison) in the difference between Hill and Plain extracts: * p < 0.05; ** p < 0.01; 3,4-DHPEA-EDA: dialdehydic form of decarboxymethyl elenolic acid linked to hydroxytyrosol (oleacein); p-HPEA-EDA: dialdehydic form of decarboxymethylelenolic acid linked to tyrosol (oleocanthal); 3,4-DHPEA-EA: isomer of oleuropein aglycone; p-HPEA-EA: ligstroside aglycon.
Figure 1Viability of differentiated SH-SY5Y treated with EVOO extracts. Cells were treated with increasing concentrations (1 to 500 µg/mL) of EVOO extracts for 24 h and the cellular viability was measured by MTT assay as described in Materials and Methods. Each bar represents means ± SEM of at least three independent experiments. Data were analyzed by one-way ANOVA followed by Dunnett’s test. * p < 0.05 with respect to CTRL.
Figure 2Neuroprotective activity of EVOO extracts against H2O2 in SH-SY5Y cells. Cells were treated with 10 µg/mL of the EVOO extracts for 24 h and then exposed to H2O2. (A) Cell viability was measured by MTT assay and (B) LDH was measured as LDH activity in in the culture medium as described in Materials and Methods. Each bar represents means ± SEM of at least three independent experiments. Data were analyzed by one-way ANOVA followed by Bonferroni’s test. * p < 0.05 with respect to CTRL; ° p < 0.05 with respect to H2O2; § p < 0.05 with respect to plain.
Figure 3Antioxidant capacity of EVOO extracts. Cells were treated with 10 µg/mL of hill and plain extracts for 24 h (A) The intracellular ROS levels were measured with the peroxide-sensitive probe DCFH-DA as reported in Materials and Methods. Data are expressed as percentage of H2O2. (B) The intracellular GSH levels were evaluated using the fluorescent probe monochloro bimane (MCB) as described in Materials and Methods. Data are expressed as percentage of control (CTRL). Each bar represents means ± SEM of at least three independent experiments. Data were analyzed by one-way ANOVA followed by Dunnett’s test or Bonferroni’s test. * p < 0.05 with respect to CTRL; ° p < 0.05 with respect to H2O2.
Figure 4Expression of antioxidant enzymes in SH-SY5Y cells treated with the extracts. Cells were treated with hill and plain extracts (10 µg/mL) for 6 h. Real time-PCR was performed to detect HMOX1, TXNRD1, NQO1 and GSR mRNA levels. Data are expressed as relative abundance compared to untreated cells. Each bar represents mean ± SEM of three independent experiments. Data were analyzed with a one-way ANOVA followed by the Bonferroni’s test. * p < 0.05 vs. CTRL; § p < 0.05 vs. plain.
Figure 5Expression of BDNF in SH-SY5Y cells treated with the extracts. Cells were treated with hill and plain extracts (10 µg/mL) for 24 h. Real time-PCR was performed to detect BDNF mRNA levels. Data are expressed as relative abundance compared to untreated cells. Each bar represents mean ± SEM of three independent experiments. Data were analyzed with one-way ANOVA followed by the Bonferroni’s test. * p < 0.05 vs. CTRL; § p < 0.05 vs. plain.
Figure 62DE representative images of differentiated SH-SY5Y cell proteins treated with Hill (A) and Plain (B) extracts. Venn diagram (C) of different comparisons. (A,B) SH-SY5Y proteins were separated in a 3–10 nonlinear gradient. SDS-PAGE was performed using 12% acrylamide. Gels were stained with ruthenium. (C) Venn diagram highlighting the distribution of identified differentially expressed proteins in hill and plain extracts as compared to control. Both unique and overlapping proteins are reported as actual number and percentage (Venny 2.0.2).
List of differentially expressed proteins, which are exclusive of hill extract treated cells.
| Spot n. | Protein Name | ID | Gene | Coverage (%) | Peptides | Unic Peptide | MW (kDa) | pI | Ratio (Hill/Ctrl) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2417 | Heterogeneous nuclear ribonucleoprotein A3 | P51991 | HNRNPA3 | 29 | 10 | 10 | 39 | 9.1 | 7.84 | 0.017 |
| 2514 | ELAV-like protein 3, Iso 1,2 | Q14576 | ELAVL3 | 11, 11 | 3 | 1 | 39/38 | 9.3 | 7.3 | 0.012 |
| 1601 | Non-POU domain-containing octamer-binding protein | Q15233 | NONO | 14 | 4 | 4 | 54 | 9.0 | 4.59 | 0.03 |
| 1030 | Pyruvate dehydrogenase phosphatase regulatory subunit, mitochondrial, Iso 1 | Q8NCN5 | PDPR | 4 | 3 | 3 | 99 | 5.7 | 2.48 | 0.017 |
| 1278 | Heat shock 70 kDa protein 1A, Iso 1,2 | P0DMV8 | HSPA1A | 13 | 6 | 1 | 66/70 | 5.4/5.5 | 2.3 | 0.011 |
| 1278 | Heat shock 70 kDa protein 1B | P0DMV9 | HSPA1B | 13 | 6 | 1 | 70 | 5.4 | 2.3 | 0.011 |
| 1278 | Heat shock cognate 71 kDa protein | P11142 | HSPA8 | 34 | 18 | 14 | 71 | 5.3 | 2.29 | 0.011 |
| 1367 | Dihydropyrimidinase-related protein 3, Iso LCRMP-4 | Q14195 | DPYSL3 | 28 | 14 | 14 | 74 | 5.9 | 2.20 | 0.022 |
| 1606 | Pyruvate kinase PKM, Iso M2 | P14618 | PKM | 38 | 18 | 18 | 58 | 7.9 | 1.8 | 0.034 |
| 1085 | Membrane primary amine oxidase, Iso 1,2 | Q16853 | AOC3 | 3 | 2 | 2 | 84/70 | 6.0/7.1 | 1.8 | 0.023 |
| 1085 | Vitamin D-binding protein, Iso 1,3 | P02774 | GC | 8 | 2 | 2 | 53/55 | 5.1/5.4 | 1.77 | 0.023 |
| 894 | Filamin-A, Iso 1,2 | P21333 | FLNA | 4 | 7 | 7 | 280 | 5.7 | 1.69 | 0.016 |
| 1136 | Ezrin | P15311 | EZR | 10 | 5 | 2 | 69 | 5.9 | 1.66 | 0.005 |
| 895 | Filamin-A, Iso 1,2 | P21333 | FLNA | 3 | 6 | 6 | 280 | 5.7 | 1.54 | 0.01 |
| 1093 | ATP-dependent 6-phosphofructokinase, muscle type, Iso 1, 3 | P08237 | PFKM | 15 | 9 | 9 | 85/93 | 8.2 | 1.50 | 0.005 |
| 945 | Prolyl 3-hydroxylase 3 | Q8IVL6 | P3H3 | 6 | 4 | 4 | 82 | 5.8 | 1.50 | 0.008 |
| 1427 | Dihydropyrimidinase-related protein 2, Iso 1,2 | Q16555 | DPYSL2 | 15/16 | 5 | 5 | 62/58 | 5.9/5.7 | 1.49 | 0.033 |
| 2475 | Eukaryotic translation initiation factor 2 subunit 1 | P05198 | EIF2S1 | 30 | 7 | 7 | 36 | 5.0 | 1.46 | 0.029 |
| 569 | Hypoxia up-regulated protein 1 | Q9Y4L1 | HYOU1 | 45 | 32 | 32 | 111 | 5.1 | 1.45 | 0.014 |
| 781 | Heat shock 70 kDa protein 4 | P34932 | HSPA4 | 32 | 18 | 18 | 94 | 5.1 | 1.39 | 0.044 |
| 1485 | Very long-chain specific acyl-CoA dehydrogenase, mitochondrial, Iso 1,2,3 | P49748 | ACADVL | 4 | 2 | 2 | 70/68 | 7.7/8.7 | 1.38 | 0.001 |
| 1280 | Heterogeneous nuclear ribonucleoprotein M, Iso 1,2 | P52272 | HNRNPM | 18 | 8 | 8 | 77/74 | 8.8/ 8.9 | 1.36 | 0.019 |
| 1371 | Probable ATP-dependent RNA helicase DDX17, Iso 1,2,3,4 | Q92841 | DDX17 | 8 | 4 | 4 | 80/72 | 8.5/ 8.8 | 1.36 | 0.019 |
| 1371 | Calcium-binding mitochondrial carrier protein Aralar2, Iso 1,2 | Q9UJS0 | SLC25A13 | 17 | 8 | 8 | 74 | 8.7 | 1.36 | 0.019 |
| 2074 | Vimentin | P08670 | VIM | 27 | 10 | 10 | 53 | 5.0 | 1.34 | 0.004 |
| 952 | 26S proteasome non-ATPase regulatory subunit 2 | Q13200 | PSMD2 | 19 | 10 | 10 | 100 | 5.1 | 1.34 | 0.017 |
| 808 | Insulin-degrading enzyme | P14735 | IDE | 3 | 3 | 3 | 117 | 6.2 | 1.33 | 0.043 |
| 1216 | 78 kDa glucose-regulated protein | P11021 | HSPA5 | 46 | 30 | 30 | 72 | 5.0 | 1.29 | 0.003 |
| 2374 | Alcohol dehydrogenase class-3 | P11766 | ADH5 | 18 | 4 | 4 | 39 | 7.6 | 1.29 | 0.037 |
| 2417 | Heterogeneous nuclear ribonucleoproteins A2/B1, Iso B1 | P22626 | HNRNPA2B1 | 12 | 3 | 3 | 37 | 8.9 | 1.29 | 0.037 |
| 1413 | Prelamin-A/C, Iso A,C | P02545 | LMNA | 9 | 5 | 5 | 74/65 | 6.5/6.4 | 1.28 | 0.023 |
| 1650 | Non-POU domain-containing octamer-binding protein | Q15233 | NONO | 25 | 9 | 9 | 54 | 9.0 | 1.28 | 0.041 |
| 901 | Programmed cell death 6-interacting protein, Iso 1,2 | Q8WUM4 | PDCD6IP | 21 | 11 | 11 | 96 | 1.28 | 0.006 | |
| 1371 | Heterogeneous nuclear ribonucleoprotein M, Iso 1,2 | P52272 | HNRNPM | 16/17 | 8 | 8 | 77/75 | 8.8/8.9 | 1.27 | 0.023 |
| 1461 | Asparagine--tRNA ligase, cytoplasmic | O43776 | NARS | 31 | 13 | 13 | 63 | 5.9 | 1.26 | 0.037 |
| 1467 | Prelamin-A/C, Iso A,C | P02545 | LMNA | 16/19 | 9 | 9 | 74/65 | 6.5/6.4 | 1.26 | 0.043 |
| 811 | Neutral alpha-glucosidase AB, Iso 1,2 | Q14697 | GANAB | 10 | 8 | 8 | 106/109 | 1.26 | 0.001 | |
| 1012 | Gelsolin, Iso 1,2,3,4 | P06396 | GSN | 6 | 3 | 3 | 85/80 | 5.7/5.5 | 1.24 | 0.041 |
| 1363 | Lamin-B1 | P20700 | LMNB1 | 33 | 20 | 20 | 66 | 5.1 | 1.24 | 0.03 |
| 1330 | Beta-catenin-like protein 1, Iso 1,4 | Q8WYA6 | CTNNBL1 | 7 | 2 | 2 | 65/61 | 4.9/5.0 | 1.24 | 0.03 |
| 1330 | Ubiquilin-2 | Q9UHD9 | UBQLN2 | 5 | 2 | 2 | 65 | 5.1 | 1.24 | 0.03 |
| 1084 | Neurosecretory protein VGF | O15240 | VGF | 14 | 6 | 6 | 67 | 4.7 | 1.22 | 0.013 |
| 1084 | Secretogranin-2 | P13521 | SCG2 | 14 | 7 | 7 | 71 | 4.6 | 1.22 | 0.013 |
| 2593 | Elongation factor 1-delta, Iso 1,2 | P29692 | EEF1D | 26 | 6 | 6 | 31 | 4.9/6.0 | 1.16 | 0.015 |
| 1427 | Phosphoacetylglucosamine mutase, Iso 1,2,3 | O95394 | PGM3 | 6 | 3 | 3 | 59/62 | 5.8/5.6 | 1.07 | 0.023 |
| 3410 | Proteasome subunit alpha type-2 | P25787 | PSMA2 | 39 | 7 | 7 | 26 | 7.1 | 0.81 | 0.002 |
| 2315 | Actin, cytoplasmic 1 | P60709 | ACTB | 11 | 4 | 4 | 42 | 5.2 | 0.75 | 0.014 |
| 2315 | Actin, cytoplasmic 2 | P63261 | ACTG1 | 11 | 4 | 4 | 42 | 5.3 | 0.75 | 0.014 |
| 1979 | Ribonuclease inhibitor | P13489 | RNH1 | 19 | 6 | 6 | 50 | 4.7 | 0.73 | 0.017 |
| 2230 | DNA-directed RNA polymerases I and III subunit RPAC1, Iso 1,2 | O15160 | POLR1C | 17/16 | 4 | 4 | 39/38 | 5.3/5.6 | 0.67 | 0.007 |
| 2830 | Voltage-dependent anion-selective channel protein 2, Iso 1,2,3 | P45880 | VDAC2 | 15/16 | 3 | 3 | 33/30 | 7.5/6.8 | 0.66 | 0.023 |
List of common differentially expressed proteins.
| Spot n. | Protein Name | ID | Gene | Coverage (%) | Peptides | Unic Peptides | MW | pI | Ratio (Plain/Ctrl) | Ratio (Hill/Ctrl) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2164 | Heterogeneous nuclear ribonucleoprotein D0 Iso 1,3 | Q14103 | HNRNPD | 9/10 | 2 | 2 | 38/32 | 7.6/8.2 | 1.77 | 1.44 | 0.005 |
| 2164 | Citrate synthase mitochondrial | O75390 | CS | 8 | 3 | 3 | 52 | 7.4 | 1.77 | 1.44 | 0.005 |
| 2164 | Protein arginine methyltransferase NDUFAF7 mitochondrial | Q7L592 | NDUFAF7 | 8 | 3 | 3 | 49 | 7.3 | 1.77 | 1.44 | 0.005 |
| 2164 | Cytochrome b-c1 complex subunit 2. mitochondrial | P22695 | UQCRC2 | 14 | 4 | 4 | 48 | 7.7 | 1.77 | 1.44 | 0.005 |
| 1001 | Pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 | O43143 | DHX15 | 14 | 9 | 9 | 91 | 7.1 | 1.72 | 1.49 | 0.009 |
| 5503 | MICOS complex subunit MIC60, Iso 1,2, 4 | Q16891 | IMMT | 31/31 | 17 | 1 | 83/ 82 | 5.7/6.1 | 1.66 | 1.75 | 0.019 |
| 1057 | X-ray repair cross-complementing protein 5 | P13010 | XRCC5 | 13 | 7 | 7 | 83 | 5.5 | 1.62 | 1.43 | 0.0006 |
| 1993 | 26S proteasome regulatory subunit 7 | P35998 | PSMC2 | 38 | 14 | 14 | 48 | 5.7 | 1.58 | 1.23 | 0.005 |
| 881 | Elongation factor 2 | P13639 | EEF2 | 9 | 6 | 6 | 95 | 6.4 | 1.58 | 1.29 | 0.033 |
| 726 | Vinculin, Iso 1,2 | P18206 | VCL | 16/15 | 9 | 9 | 116/124 | 5.8/5.5 | 1.38 | 1.63 | 0.028 |
| 2654 | Annexin A2, Iso 1,2 | P07355 | ANXA2 | 46/44 | 18 | 18 | 38/40 | 7.5/ 8.5 | 1.24 | 1.22 | 0.036 |
| 3761 | Adenine phosphoribosyltransferase, Iso 1,2 | P07741 | APRT | 23/31 | 3 | 3 | 19/14 | 5.7/6.7 | 0.87 | 0.81 | 0.036 |
| 3761 | DNA-directed RNA polymerase II subunit RPB7 | P62487 | POLR2G | 23 | 3 | 3 | 19 | 5.3 | 0.87 | 0.81 | 0.036 |
| 3549 | Eukaryotic translation initiation factor 3 subunit K, Iso 1,2 | Q9UBQ5 | EIF3K | 11 | 2 | 2 | 25/24 | 4.8. 4.7 | 0.7 | 0.73 | 0.013 |
| 3549 | Proteasome subunit beta type-6 | P28072 | PSMB6 | 18 | 4 | 4 | 25 | 4.9 | 0.7 | 0.73 | 0.013 |
| 3549 | Translationally-controlled tumor protein | P13693 | TPT1 | 34 | 5 | 5 | 19 | 4.8 | 0.7 | 0.73 | 0.013 |
| 3977 | Diablo homolog. Mitochondrial, Iso 1,2 | Q9NR28 | DIABLO | 27/34 | 6 | 6 | 27/21 | 4.7/4.8 | 0.58 | 0.52 | 0.003 |
| 3977 | Ras-related protein Rap-2a | P10114 | RAP2A | 10 | 2 | 2 | 20 | 4.73 | 0.58 | 0.52 | 0.003 |
List of top eight upstream regulators obtained by IPA analysis of differentially expressed proteins in hill extract treated SH-SY5Y cells.
| Upstream Regulator | Molecule Type | Activation z-Score | Target Molecules | |
|---|---|---|---|---|
| TP53 | Transcription regulator | 0.295 | 8.48 × 10−11 | ACADVL, ACTB, ADH5, ANXA2, CS, EZR, GC, GSN, HNRNPA2B1, HSPA1A/HSPA1B, HSPA8, NARS1, |
| MAPT | Other | 7.74 × 10−9 | ACTB, ACTG1, CS, DPYSL2, DPYSL3, EEF2, HSPA1A/HSPA1B, HSPA5, HSPA8, PKM, PSMD2 | |
| BDNF | Growth factor | 0.29 | 2.53 × 10−7 | ANXA2, DPYSL3, EEF1D, EEF2, FLNA, HSPA5, RNH1, VGF, VIM |
| IL5 | Cytokine | 2.236 | 1.25 × 10−3 | ANXA2, HSPA5, LMNB1, PKM, VIM |
| SP1 | Transcription regulator | 2.211 | 5.07 × 10−3 | ADH5, EZR, FLNA, HSPA5, PKM, VIM |
| FGF2 | Growth factor | 2.391 | 1.1 × 10−3 | FLNA, LMNA, SCG2, VGF, VIM, XRCC5 |
| RET | Kinase | 2.186 | 1.6 × 10−5 | DPYSL2, HSPA1A/HSPA1B, HSPA8, UBQLN2, VGF |
| MYC | Transcription regulator | 2.185 | 1.32 × 10−5 | ACTB, EEF2, EIF2S1, EZR, FLNA, HNRNPA2B1, HNRNPD, NARS1, PFKM, PKM, POLR2G, VDAC2, VIM |
Figure 7Regulator network generated by IPA. Upstream regulators (SP1, IL5, FGF2 and RET) are displayed in the top tier while functions are displayed in the bottom tier. The data set proteins connecting regulators and lower functions are shown in the middle tier where the fold change value of each protein expression is reported below the gene name. The predicted regulators had a z-score (activation score) > 1.9 and a Fisher’s exact p-value < 0.05. Dashed lines are indirect effects and the protein shape indicates the protein class (defined by IPA). Orange and cyan connecting lines indicate activation and inhibition, respectively. Similarly, activated and inhibited downstream functions are orange and cyan. * More than one spot was identified for this protein.
Figure 8WB analysis of BDNF (A) and DPYSL2 (B) expression in SH-SY5Y cells treated with and without EVOO extracts. Representative immunoblot images and histograms of band normalized OD are shown. Data are presented as mean ± SEM of three independent experiments. Data were analyzed with a one-way ANOVA followed by the Bonferroni’s test. * p < 0.05 vs. CTRL; § p < 0.05 vs. plain.